parkinson's disease triple agonist glp-1 gip glucagon clinical trial Timeline of discovery and development. (a) Key events in... Frontiers | Glucagon-like peptide 1

Tirzepatide displayed an unprecedented glucose and body weight lowering potential, presenting also with the ability to increase insulin sensitivity, reduce systolic blood pressure and inflammation and ameliorate dyslipidemia, particularly by reducing triglycerides levels

From a scientific breakthrough studying the oft fasting Gila Monster has become the current successful weight loss therapies, here's how.

GoodRx reports that GLP-1 medications will expand in use and accessibility, with new oral options and evolving insurance coverage trends.

Purpose Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes (T2D), and CKD-related disability and mortality are increasing despite the recent advances in diabetes management